🟢 Marker Therapeutics is trading 7% up — no clear catalyst identified

Marker Therapeutics is trading 7.03% up at $0.97, with no clear company-specific catalyst identified for October 27, 2026.

• The latest company news located is an October 19 FDA award of a $2.6 million grant for a planned Phase 1 MT-601 pancreatic cancer study; it predates the move and does not establish its cause.
• Broader indexes are mixed, and available evidence does not point to a clear market-wide explanation.